Sumitomo Mitsui Trust Group Inc. Buys 13,102 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Sumitomo Mitsui Trust Group Inc. grew its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 11.7% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 125,097 shares of the medical research company’s stock after acquiring an additional 13,102 shares during the period. Sumitomo Mitsui Trust Group Inc. owned about 0.24% of Charles River Laboratories International worth $23,093,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in CRL. Virtu Financial LLC purchased a new stake in Charles River Laboratories International in the third quarter worth $601,000. JPMorgan Chase & Co. boosted its holdings in shares of Charles River Laboratories International by 21.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after buying an additional 85,759 shares in the last quarter. State Street Corp grew its position in shares of Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after buying an additional 41,421 shares during the period. Janus Henderson Group PLC increased its stake in shares of Charles River Laboratories International by 7.6% in the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock worth $9,064,000 after acquiring an additional 3,268 shares in the last quarter. Finally, Neo Ivy Capital Management purchased a new position in Charles River Laboratories International during the 3rd quarter valued at about $966,000. Institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

CRL has been the subject of a number of analyst reports. UBS Group reaffirmed a “neutral” rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Evercore ISI raised their price objective on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. The Goldman Sachs Group dropped their target price on Charles River Laboratories International from $220.00 to $190.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. TD Cowen raised their price target on Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a report on Monday, November 11th. Finally, William Blair cut shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Three equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating and one has assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $200.79.

Charles River Laboratories International Trading Down 3.1 %

NYSE:CRL opened at $154.93 on Wednesday. The company has a market cap of $7.92 billion, a PE ratio of 19.39, a price-to-earnings-growth ratio of 6.47 and a beta of 1.37. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The company has a 50 day simple moving average of $178.90 and a two-hundred day simple moving average of $192.24. Charles River Laboratories International, Inc. has a 12 month low of $154.01 and a 12 month high of $275.00.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).